Trial Profile
Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Futibatinib (Primary) ; Ivosidenib (Primary) ; Neratinib (Primary) ; Niraparib (Primary) ; Trastuzumab (Primary) ; Zanidatamab (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms SAFIR-ABC10
- 09 Apr 2024 Planned initiation date changed from 1 Jan 2024 to 1 Apr 2024.
- 15 Nov 2023 Planned initiation date changed from 1 Oct 2023 to 1 Jan 2024.
- 28 Aug 2023 Planned initiation date changed from 1 Jun 2023 to 1 Oct 2023.